Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Research Report 2022

Report Format: PDF   |   Report ID: 5514461   |   Published Date: August 2022   |   Pages:  65  

Choose License
As for March 26, 2020
1.BCG Vaccine Clinical Experiment for Against Covid-19
Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.
Researchers in Germany are also testing VPM1002, a genetically modified version of BCG, developed by the Max Planck Institute, in a Phase 3 trial.
The partners involved, Vakzine Project Management (VPM) and the Serum Institute of India, have already held promising discussions with the authorities regarding the implementation of a Phase III study with VPM1002 in Germany in order to investigate the effectiveness of the vaccine in elderly people and healthcare workers. 'These population groups are particularly affected by the current pandemic', says Leander Grode, Managing Director of VPM 'and could therefore particularly benefit from a vaccination with VPM1002'. If the results are positive, VPM1002 could help ease the burden on healthcare systems until a vaccine specifically effective against SARS-CoV-2 becomes available.
2.Introduce of VPM1002? 1/4 ?a Genetically Modified More Effective BCG Vaccine
VPM1002 is based on a vaccine called BCG, which was developed at the beginning of the 20th century. The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB.  Studies on mice show that the BCG vaccine can protect not only against tuberculosis but also against viral infections of the respiratory tract.
The vaccine candidate, originally developed at the Max Planck Institute for Infection Biology in Berlin by the group of Stefan H.E. Kaufmann, thus provides more effective protection against tuberculosis than the old vaccine and is intended for use in new-borns as well as for boosting a vaccination in adults.
Recent studies have shown that VPM1002 can also be effective against cancer and prevent the recurrence of bladder tumours.
3.Research Progress for VPM1002
Scientists have investigated this further development of the BCG vaccine in a series of studies in mice as well as in several clinical trials. In 2018, a Phase II study confirmed that VPM1002 is well tolerated by new borns and is effective.
The vaccine is currently being tested in a further Phase III study on adult volunteers in India.
Due to the COVID-19 pandemic, the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market size is estimated to be worth US$  million in 2021 and is forecast to a readjusted size of US$  million by 2028 with a CAGR of  % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market is estimated at US$  million in 2022, while the United States and China are forecast to reach US$  million and US$  million by 2028, respectively. The proportion of the United States is  % in 2022, while Chinese percentage is  %, and it is predicted that China market share will reach  % in 2028, trailing a CAGR of  % through the analysis period. As for the Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 landscape, Germany is projected to reach US$  million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is  % and  % respectively for the next 6-year period.
0.5ml Package accounting for  % of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While 0-5 Years Old segment is altered to an  % CAGR throughout this forecast period and will hold a share about  % in 2028.
The global major manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 include Vakzine Projekt Management (VPM) and Serum Institute of India etc. In terms of revenue, the global 3 largest players have a  % market share of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 in 2021.
This report focuses on VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
    by Dosage
        0.5ml Package
        1ml Package
        2ml Package
        Other
    by Type of Inoculator
        Initial Vaccinate
        Revaccination
Segment by Application
    0-5 Years Old
    5-18 Years Old
    18-45 Years Old
    45-65 Years Old
    ???65 Years Old
By Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
By Company
    Vakzine Projekt Management (VPM)
    Serum Institute of India
1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Overview
    1.1 Product Overview and Scope of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
    1.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Segment by Dosage
        1.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Growth Rate Comparison by Dosage  (2022-2028)
        1.2.2 0.5ml Package
        1.2.3 1ml Package
        1.2.4 2ml Package
        1.2.5 Other
    1.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Segment by Application
        1.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Comparison by Application: (2022-2028)
        1.3.2 0-5 Years Old
        1.3.3 5-18 Years Old
        1.3.4 18-45 Years Old
        1.3.5 45-65 Years Old
        1.3.6 ???65 Years Old
    1.4 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size Estimates and Forecasts
        1.4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue 2017-2028
        1.4.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales 2017-2028
        1.4.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Region: 2017 Versus 2021 Versus 2028
2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Competition by Manufacturers
    2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Manufacturers (2017-2022)
    2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Manufacturers (2017-2022)
    2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Average Price by Manufacturers (2017-2022)
    2.4 Manufacturers VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturing Sites, Area Served, Product Type
    2.5 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Competitive Situation and Trends
        2.5.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Concentration Rate
        2.5.2 The Global Top 5 and Top 10 Largest VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Players Market Share by Revenue
        2.5.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Retrospective Market Scenario by Region
    3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Retrospective Market Scenario in Sales by Region: 2017-2022
    3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Retrospective Market Scenario in Revenue by Region: 2017-2022
    3.3 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Facts & Figures by Country
        3.3.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country
        3.3.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country
        3.3.3 U.S.
        3.3.4 Canada
    3.4 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Facts & Figures by Country
        3.4.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country
        3.4.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Facts & Figures by Region
        3.5.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region
        3.5.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
        3.5.12 Philippines
        3.5.13 Vietnam
    3.6 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Facts & Figures by Country
        3.6.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country
        3.6.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country
        3.6.3 Mexico
        3.6.4 Brazil
        3.6.5 Argentina
    3.7 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Facts & Figures by Country
        3.7.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country
        3.7.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 UAE
4 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Historic Market Analysis by Type
    4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2017-2022)
    4.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2017-2022)
    4.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Type (2017-2022)
5 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Historic Market Analysis by Application
    5.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2017-2022)
    5.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application (2017-2022)
    5.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Application (2017-2022)
6 Key Companies Profiled
    6.1 Vakzine Projekt Management (VPM)
        6.1.1 Vakzine Projekt Management (VPM) Corporation Information
        6.1.2 Vakzine Projekt Management (VPM) Description and Business Overview
        6.1.3 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales, Revenue and Gross Margin (2017-2022)
        6.1.4 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Portfolio
        6.1.5 Vakzine Projekt Management (VPM) Recent Developments/Updates
    6.2 Serum Institute of India
        6.2.1 Serum Institute of India Corporation Information
        6.2.2 Serum Institute of India Description and Business Overview
        6.2.3 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales, Revenue and Gross Margin (2017-2022)
        6.2.4 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Portfolio
        6.2.5 Serum Institute of India Recent Developments/Updates
7 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturing Cost Analysis
    7.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
    7.4 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Distributors List
    8.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Customers
9 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Dynamics
    9.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Industry Trends
    9.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Drivers
    9.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Challenges
    9.4 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Restraints
10 Global Market Forecast
    10.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Estimates and Projections by Type
        10.1.1 Global Forecasted Sales of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Type (2023-2028)
        10.1.2 Global Forecasted Revenue of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Type (2023-2028)
    10.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Estimates and Projections by Application
        10.2.1 Global Forecasted Sales of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Application (2023-2028)
        10.2.2 Global Forecasted Revenue of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Application (2023-2028)
    10.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Region (2023-2028)
        10.3.2 Global Forecasted Revenue of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer

List of Tables Table 1. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Growth Rate Comparison by Type (2022-2028) & (K Doses) & (US$ Million) Table 2. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Growth Rate Comparison by Application (2022-2028) & (K Doses) & (US$ Million) Table 3. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Region (US$ Million) (2017 VS 2021 VS 2028) Table 4. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Competitive Situation by Manufacturers in 2021 Table 5. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses) of Key Manufacturers (2017-2022) Table 6. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Manufacturers (2017-2022) Table 7. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (US$ Million) by Manufacturers (2017-2022) Table 8. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Manufacturers (2017-2022) Table 9. Global Market VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Average Price (USD/Dose) of Key Manufacturers (2017-2022) Table 10. Manufacturers VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturing Sites and Area Served Table 11. Manufacturers VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 as of 2021) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2017-2022) & (K Doses) Table 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2017-2022) Table 17. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2017-2022) & (US$ Million) Table 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Region (2017-2022) Table 19. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2017-2022) & (K Doses) Table 20. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2017-2022) Table 21. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2022) & (US$ Million) Table 22. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2017-2022) Table 23. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2017-2022) & (K Doses) Table 24. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2017-2022) Table 25. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2022) & (US$ Million) Table 26. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2017-2022) Table 27. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2017-2022) & (K Doses) Table 28. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2017-2022) Table 29. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2017-2022) & (US$ Million) Table 30. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Region (2017-2022) Table 31. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2017-2022) & (K Doses) Table 32. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2017-2022) Table 33. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2022) & (US$ Million) Table 34. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2017-2022) Table 35. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2017-2022) & (K Doses) Table 36. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2017-2022) Table 37. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2022) & (US$ Million) Table 38. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2017-2022) Table 39. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2022) & (K Doses) Table 40. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2017-2022) Table 41. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2017-2022) & (US$ Million) Table 42. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Type (2017-2022) Table 43. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Type (2017-2022) & (USD/Dose) Table 44. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses) by Application (2017-2022) Table 45. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2017-2022) Table 46. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2017-2022) & (US$ Million) Table 47. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Application (2017-2022) Table 48. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Application (2017-2022) & (USD/Dose) Table 49. Vakzine Projekt Management (VPM) Corporation Information Table 50. Vakzine Projekt Management (VPM) Description and Business Overview Table 51. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 52. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Table 53. Vakzine Projekt Management (VPM) Recent Developments/Updates Table 54. Serum Institute of India Corporation Information Table 55. Serum Institute of India Description and Business Overview Table 56. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 57. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Table 58. Serum Institute of India Recent Developments/Updates Table 59. Production Base and Market Concentration Rate of Raw Material Table 60. Key Suppliers of Raw Materials Table 61. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Distributors List Table 62. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Customers List Table 63. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Trends Table 64. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Drivers Table 65. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Challenges Table 66. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Restraints Table 67. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Type (2023-2028) & (K Doses) Table 68. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share Forecast by Type (2023-2028) Table 69. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Type (2023-2028) & (US$ Million) Table 70. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share Forecast by Type (2023-2028) Table 71. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Application (2023-2028) & (K Doses) Table 72. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share Forecast by Application (2023-2028) Table 73. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Application (2023-2028) & (US$ Million) Table 74. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share Forecast by Application (2023-2028) Table 75. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Forecast by Region (2023-2028) & (K Doses) Table 76. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share Forecast by Region (2023-2028) Table 77. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Forecast by Region (2023-2028) & (US$ Million) Table 78. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share Forecast by Region (2023-2028) Table 79. Research Programs/Design for This Report Table 80. Key Data Information from Secondary Sources Table 81. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Figure 2. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Share by Type in 2021 & 2028 Figure 3. 0.5ml Package Product Picture Figure 4. 1ml Package Product Picture Figure 5. 2ml Package Product Picture Figure 6. Other Product Picture Figure 7. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Share by Application in 2021 & 2028 Figure 8. 0-5 Years Old Figure 9. 5-18 Years Old Figure 10. 18-45 Years Old Figure 11. 45-65 Years Old Figure 12. ???65 Years Old Figure 13. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 14. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size (2017-2028) & (US$ Million) Figure 15. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (2017-2028) & (K Doses) Figure 16. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Share by Manufacturers in 2021 Figure 17. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Manufacturers in 2021 Figure 18. The Global 5 and 10 Largest VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Players: Market Share by Revenue in 2021 Figure 19. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021 Figure 20. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2017-2022) Figure 21. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region in 2021 Figure 22. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Region (2017-2022) Figure 23. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Region in 2021 Figure 24. U.S. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 25. Canada VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 26. Germany VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 27. France VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 28. U.K. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 29. Italy VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 30. Russia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 31. China VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 32. Japan VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 33. South Korea VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 34. India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 35. Australia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 36. Taiwan VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 37. Indonesia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 38. Thailand VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 39. Malaysia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 40. Philippines VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 41. Vietnam VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 42. Mexico VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 43. Brazil VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 44. Argentina VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 45. Turkey VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 46. Saudi Arabia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 47. UAE VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Growth Rate (2017-2022) & (US$ Million) Figure 48. Sales Market Share of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Type (2017-2022) Figure 49. Manufacturing Cost Structure of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Figure 50. Manufacturing Process Analysis of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Figure 51. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Industrial Chain Analysis Figure 52. Channels of Distribution Figure 53. Distributors Profiles Figure 54. Bottom-up and Top-down Approaches for This Report Figure 55. Data Triangulation Figure 56. Key Executives Interviewed

This research study involved the extensive usage of both primary and secondary data sources.  The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for manufacturers, regions segments, product segments and applications (end users). All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from QYResearch and presented in this report.
 

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
 

Secondary Sources occupies Approximately 25% of Sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on; This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; BIS Statistics; ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Light Aircraft market. It was also used to obtain important information about the top players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
 

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers etc.
 

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
 

Primary research was conducted to identify segmentation types, product price range, product applications, key players, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
 

Publisher: QY Research
Chat with us